You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

54 search results for: asthma

expert video

The Risks of Associated Systemic and Atopic Comorbidities with AD

5 min

Dermatology

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

Clinical Manifestations Associated With Airway Remodeling in <b>Asthma</b>

expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

2 min

Type 2 Inflammation

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Why Is It Important to Assess Lung Function in Pediatric Severe <b>Asthma</b> Patients?

expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

18 min

Pulmonology

Prof. Monika Gappa presents the importance in assessment of lung function in pediatric patients alongside the associated patient burden.

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, <b>Asthma</b>, CRSwNP, and EoE

Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

5 min

Type 2 Inflammation

Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases

expert video

ERS 2024 | Can Biologics Affect Airway Remodeling?

20 min

Pulmonology

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

expert video

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

12 min

Pulmonology

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

expert video

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

2 min

Rhinology

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

30 min

Pulmonology

Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.

videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

5 min

Type 2 Inflammation

This video highlights type 2 inflammation as the common thread that links AD, asthma, CRSwNP, and EoE.

expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

10 min

Type 2 Inflammation

Prof. Oscar Palomares discusses the underlying pathophysiology of type 2 inflammation in pediatric patients with AD, asthma, or EoE.

expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

40 min

Type 2 Inflammation

Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type 2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: EcuadorChange country/region